dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English

04.05.2020: AC Immune SA

AC Immune Reports Q1 2020 Financial Results and Provides Business Update

  • On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19
  • Ongoing strong financial position with CHF 277.9 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones
  • Added new potential CHF 60 million Phase 2 initiation milestone for the small molecule Morphomerâ„¢ Tau aggregation inhibitor program and received CHF 10 million milestone in Q1 2020 in Lilly partnership
  • Advanced a lead anti-alpha-synuclein therapeutic antibody candidate into preclinical development based on new proof-of-concept data presented at AAT-AD/PDTM

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2020 and
provided a business and 2020 research and development update.

Den gesamten Artikel lesen Sie bitte hier
AC Immune SA, News 2020
30.04.2020: Cassiopea SpA
14.05.2020: CureVac AG

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz